Compare Cassava Sciences Inc (FLNA) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Jones Lang LaSalle Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Jones Lang LaSalle Inc trades at $362.41 (market cap $16.44B). The key difference: Jones Lang LaSalle Inc is far larger — about 344.3× Cassava Sciences Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JLL | |
|---|---|---|
Market Cap | $47.75M | $16.44B |
Sector | Health | Real Estate |
52-Week High | $4.64 | $373.24 |
52-Week Low | $0.87 | $280.16 |
Enterprise Value | -$34.93M | $19.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
JLL trades at $362.38, down 0.36% on the day, near its 52-week high. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M, and analysts project further growth in 2026. Positive sentiment is driven by strong Q2 2026 results and AI-related real estate demand highlighted in recent company research.
Outlook remains positive with a consensus price target of $391.50, though risks include market volatility and execution challenges in capital markets. The stock offers growth potential from expanding profit margins and strategic positioning in AI-impacted real estate sectors, balanced by economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
